Contineum has two drug candidates in clinical trials, PIPE-791, an LPA1 receptor antagonist in clinical development for ...
the timing and design of the Company’s amylin receptor agonist program and its potential as a promising approach to obesity treatment; the timing and design of the Company’s GIPR and GLP-1R/GIPR and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback